Novo: Our focus is on drugs and pen systems
Development of pumps and monitoring devices is a speciality and a technology that we are not currently involved with, says a Novo director, who points out that drugs and pen systems are the Danish company’s core competences. Sanofi has a different view of the booming market for glucose monitors and insulin pumps.
BARCELONA
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Diabetics can look forward to a range of new devices
For abonnenter
Novo Nordisk presents positive Tresiba data
For abonnenter
Novo-chief: Uncommitted workers are dangerous
For abonnenter
